MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00415-026-13890-2

Медицинская библиотека · Journal of neurology · 2026

Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients.

Jander Alina, Bergner Sarah, Schönwald Beate, Pötter-Nerger Monika, Buhmann Carsten, Hidding Ute

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion is approved for treating motor fluctuations and dyskinesias in patients with advanced Parkinson's disease (aPD). However, efficacy data on non-motor symptoms (NMS) are limited.

OBJECTIVES

To evaluate the effects of LDp/CDp treatment on NMS in patients with aPD.

DESIGN

Retrospective analysis of efficacy of LDp/CDp on NMS after 3 week therapy in a Parkinson's day-clinic setting and further 6 weeks of outpatient treatment.

METHODS

Twenty-one patients with aPD were assessed at baseline (T0), after 3 weeks (T1), and after 9 weeks (T2). Assessments included broader NMS according to MDS-UPDRS Part I and NMS questionnaire (NMSQ) and in more detail sleep (PDSS-2) and depression (BDI-2).

RESULTS

Mean MDS-UPDRS I total score significantly improved by 27% at T1 and 34% at T2 (3.90 and 4.85 points, respectively), which has to be considered clinically relevant (threshold -2.64 points). Relevant improvement accounted for 62% of patients at T1 and 57% at T2. MDS-UPDRS part IB score also improved significantly at both timepoints by approximately 30%. The greatest benefits were observed in sleep disturbances, pain, and constipation. NMSQ score improved by 21% at T1 and 27% at T2, particularly within the gastrointestinal domain. PDSS-2 score improved by 27% at T1, and Beck Depression Inventory 2 score by 37% at T1; both showed numerical but non-significant trends at T2. Psychotic symptoms occurred as adverse effects in 4 of 21 patients (19%).

CONCLUSION

In this exploratory retrospective cohort, LDp/CDp therapy improved clinically relevant NMS, though confirmation in larger controlled studies is needed.

Для цитирования: Jander Alina, Bergner Sarah, Schönwald Beate, Pötter-Nerger Monika, Buhmann Carsten, Hidding Ute. Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients.. Journal of neurology. 2026. DOI: 10.1007/s00415-026-13890-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.